Skip to main content
Log in

NICE news on palbociclib, larotrectinib and entrectinib

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. NICE. Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund Internet Document : 16 Jan 2020. Available from: URL: https://www.nice.org.uk/news/article/breast-cancer-patients-to-have-further-nice-approved-drug-combination-option-on-cancer-drugs-fund-2

  2. NICE. NICE encourages further data collection on 'game changing' histology independent cancer drugs. Internet Document : 17 Jan 2020. Available from: URL: https://www.nice.org.uk/news/article/nice-encourages-further-data-collection-on-game-changing-histology-independent-cancer-drugs

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE news on palbociclib, larotrectinib and entrectinib. PharmacoEcon Outcomes News 845, 34 (2020). https://doi.org/10.1007/s40274-020-6537-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6537-7

Navigation